U.S. flag

An official website of the United States government

Skip to main page content
Completed

Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis (SAPRIS-SERO)

ClinicalTrials.gov ID NCT04392388
Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Information provided by Institut National de la Santé Et de la Recherche Médicale, France (Responsible Party)
Last Update Posted 2024-02-21
Bookmark

Study Overview

Brief Summary
This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and NutriNet-Santé cohorts.
Detailed Description

The primary objective is to assess the cumulative incidence of infection in the general population using dried blood spot sampling.

The secondary objectives are:

  • To identify factors associated with a positive SARS-CoV-2 infection (positive serology) and to characterize the durability of the serological response to SARS-CoV-2
  • To identify associations of symptoms predictive of a SARS-CoV-2 infection
  • To estimate the health care use associated with a SARS-CoV-2 infection
  • To estimate the fraction of sub-clinical infections or infections not captured by the healthcare system;
  • To study the acceptability of a mass anti-SARS-CoV-2 serological testing and the impact of its result, linked with social inequalities in health;
  • To estimate the individual and collective impact of containment and other preventive measures on the risk of SARS-CoV-2 infection;
  • To study the impact of social and territorial inequalities on seroprevalence levels.
Show less
Official Title
Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - Serology
Conditions
SARS-CoV 2
Intervention / Treatment
  • Biological: Non applicable
  • Biological: Non applicable
Other Study ID Numbers
  • C20-26
  • 2020-A01195-34 ( Other Identifier ) (OTHER: ID RCB (ANSM))
    2020-A01195-34 ( Other Identifier ) (OTHER: ID RCB (ANSM))
Study Start (Actual)
2020-05-01
Primary Completion (Actual)
2022-12-31
Study Completion (Actual)
2023-04-11
Enrollment (Actual)
96883
Study Type
Observational

Contacts and Locations

This section provides contact details for people who can answer questions about joining this study, and information on where this study is taking place.

To learn more, please see the Contacts and Locations section in How to Read a Study Record(https://clinicaltrials.gov/study-basics/how-to-read-study-record#contacts-and-locations).

This study has 1 location
France
Paris, France

Inserm
Click to view interactive map

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies(https://clinicaltrials.gov/study-basics/learn-about-studies).
Eligibility Criteria
Description

Inclusion Criteria:

  • non applicable, already enrolled in the cohorts

Exclusion Criteria:

  • non applicable
Show less
Study Population
Participants from cohorts entitled : Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé
Ages Eligible for Study
(ChildAdultOlder Adult )
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

/
Design Details
Observational Model : Cohort
Time Perspective: Prospective
Biospecimen Retention: Samples Without DNA
Biospecimen Description: serology samples

Groups and Interventions

Groups/Cohorts Intervention/Treatment
Groups/Cohorts SAPRIS-SERO
SAPRIS-SERO enrolls participants from cohorts entitled: Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé.
Intervention/Treatment Biological: Non applicable
  • to collect data from questionnaires and to collect serological samples

Primary Outcome Measures
Outcome Measure Measure Description Time Frame
Cumulative incidence of SARS-Cov2 infection in the general population.Simple and corrected estimate of the number of seropositive individuals/number of individuals at risk in different strata, based on weighting and calibration and taking into account the random cohort effect.8 months
Secondary Outcome Measures
Outcome Measure Measure Description Time Frame
Maintenance over time of the acquisition of anti-SARS-Cov2 antibodiesDecay kinetics estimated by mixed effect model with repeated data per subject8 months
Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infectionRate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection during a time frame of 8 months8 months
Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social determinantsProportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social déterminants during a time frame of 8 months.8 months
Proportion of tests proposed, accepted, performed, based on social and demographic characteristicsProportion of tests proposed, accepted, performed, based on social and demographic characteristics during a time frame of 8 months.8 months
Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalenceProportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence during a time frame of 8 months8 months
Strengths of associations between socio-behavioral factors and level of seroprevalenceStrengths of associations between socio-behavioral factors and level of seroprevalence during a time frame of 8 months8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
  • Principal Investigator:Fabrice Carrat, MD,Inserm - Sorbonne Université

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
2020-05-15
First Submitted that Met QC Criteria
2020-05-15
First Posted
2020-05-18
Study Record Updates
Last Update Submitted that met QC Criteria
2024-02-20
Last Update Posted
2024-02-21
Last Verified
2024-02

More Information

/

Keywords Provided by Institut National de la Santé Et de la Recherche Médicale, France

Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
IPD sharing is managed via the cohorts (Constances, E3N/E4N, NutriNetSante, Elfe/Epipage2) specific governing bodies.